From Nicotine & Tobacco Research:
https://academic.oup.com/ntr/article/22/Supplement_1/S96/6035090

In August 2019, the Centers for Disease Control and Prevention (CDC), U.S. Food and Drug Administration, state and local health departments, and other clinical and public health partners began investigating a multistate outbreak of severe lung injuries that were first identified in July 2019 in Wisconsin and Illinois among persons with a reported history of e-cigarette, or vaping, product use.  An ensuing investigation focused on understanding the extent, characteristics, and causes of the novel clinical syndrome, which was subsequently termed e-cigarette, or vaping, product use-associated lung injury (EVALI).  As of February 18, 2020, a total of 2,807 hospitalized EVALI cases were reported to CDC from all 50 states, D.C., and two U.S. territories; 68 deaths were confirmed in 29 states and D.C. National emergency department data and active case reporting from state health departments documented a sharp increase in EVALI cases in August 2019, with case counts peaking in September 2019 and then steadily declining through early 2020.

This commentary describes the evidence-based approach used to identify the primary cause of EVALI and to curb the 2019 outbreak.  We also discuss future research opportunities and public health practice considerations to prevent a resurgence of EVALI.

The article is available online from the journal Nicotine & Tobacco Research:
https://academic.oup.com/ntr/article/22/Supplement_1/S96/6035090